Editas Medicine Inc Stock Price, News & Analysis

Editas Medicine (Nasdaq: EDIT), a clinical-stage gene editing company, has announced its participation in four upcoming investor conferences in September and October 2024. The company's management will engage in fireside chat discussions about Editas and its programs, including reni-cel.

The conferences include:

• Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 in New York
• 2024 Wells Fargo Healthcare Conference on September 5 in Boston
• 2024 Cantor Global Healthcare Conference on September 17 in New York
• Chardan 8th Annual Genetic Medicines Conference on October 1 in New York

Live webcasts of Editas Medicine's presentations will be available on the company's website, with archived replays accessible for approximately 30 days after each event.

Editas Medicine (Nasdaq: EDIT) reported its Q2 2024 results and provided business updates. The company is on track to present additional clinical data from the RUBY trial for sickle cell disease and the EdiTHAL trial for beta thalassemia by year-end. Editas also aims to establish in vivo preclinical proof-of-concept for an undisclosed indication by year-end.

Financial highlights include:

• Cash, cash equivalents, and marketable securities of $318.3 million as of June 30, 2024
• Net loss of $67.6 million, or $0.82 per share
• Research and development expenses increased to $54.2 million

The company expects its current financial position to fund operations into 2026.

Editas Medicine (Nasdaq: EDIT), a clinical-stage gene editing company, has announced a conference call and webcast scheduled for August 7, 2024, at 8:00 a.m. ET. The event will cover the company's second quarter 2024 results and provide a corporate update. Interested parties can access the call via phone or webcast, with U.S. callers dialing +1-800-343-4849 and international callers using +1-203-518-9848. The webcast will be available on the company's website, and a replay will be accessible approximately one hour after the call concludes.

Editas Medicine has announced new safety and efficacy data for its gene-edited cell therapy, renizgamglogene autogedtemcel (reni-cel), from the RUBY trial, which included 18 patients with severe sickle cell disease (SCD). The data, presented at the European Hematology Association (EHA) Congress, shows that all patients treated with reni-cel experienced no vaso-occlusive events post-treatment, with follow-ups ranging up to 22.8 months.

Patients exhibited early normalization of total hemoglobin levels, averaging above 14 g/dL, and sustained improvements in fetal hemoglobin levels, exceeding 40%. The treatment was well-tolerated, with no serious adverse events reported. Editas has now dosed over 20 patients in the RUBY trial and completed adult cohort enrollment, with adolescent cohort enrollment underway.

Editas Medicine has unveiled new safety and efficacy data from the Phase 1/2 EdiTHAL trial of reni-cel in 7 patients with transfusion-dependent beta thalassemia (TDT). The gene-edited cell therapy showed promising results, with all patients maintaining hemoglobin levels above the transfusion threshold and remaining transfusion-free for 4.1 to 12.8 months post-treatment. The therapy was well-tolerated, showing a safety profile consistent with myeloablative conditioning and autologous hematopoietic stem cell transplant. These findings were presented at the European Hematology Association (EHA) Annual Congress. Reni-cel aims to be a one-time, durable treatment for TDT.

Editas Medicine (Nasdaq: EDIT) will present clinical data from two trials of renizgamglogene autogedtemcel (reni-cel) at the European Hematology Association (EHA) Hybrid Congress in Madrid, Spain, June 13-16, 2024. The RUBY trial (Phase 1/2/3) involves patients with severe sickle cell disease and will include efficacy and safety data on 18 patients with up to 21 months of follow-up. The EdiTHAL trial (Phase 1/2) targets transfusion-dependent beta thalassemia and will share data on seven patients with up to 12 months of follow-up. The presentations will include key metrics like total hemoglobin, fetal hemoglobin, and vaso-occlusive events. The company sees these updates as significant steps toward proving reni-cel as a durable, one-time treatment.

Editas Medicine showcased preclinical data at the American Society of Gene and Cell Therapy Annual Meeting, highlighting advancements in in vivo gene editing technologies. The research included the first-ever application of AsCas12a in vivo, optimized LNP delivery, and gene editing RNA guide modifications. The data supports the development of Editas Medicine's pipeline of in vivo gene editing medicines, demonstrating therapeutic promise and potential proof of concept by the end of the year.

Editas Medicine reported financial results for the first quarter of 2024, highlighting completion of adult cohort enrollment and patient dosing in the adolescent cohort for the RUBY trial for severe sickle cell disease. They are on track to present clinical data in mid-2024. The company is also enrolling patients in the EdiTHAL trial for transfusion-dependent beta thalassemia, presenting pre-clinical data at ASGCT, maintaining a strong financial position until 2026, and extending collaboration with Bristol Myers Squibb. Editas Medicine aims to establish in vivo preclinical proof-of-concept for an undisclosed indication by year-end.

Editas Medicine, Inc. (Nasdaq: EDIT) will host a conference call on May 8, 2024, to discuss first quarter 2024 results and provide a corporate update. The company will also participate in several upcoming investor events, including the Bank of America Health Care Conference and RBC Capital Markets Global Healthcare Conference.